D. De Graeve et al., Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium, PHARMACOECO, 17(6), 2000, pp. 591-601
Objective: To analyse the direct medical costs and effectiveness of vaccina
ting adults aged between 18 and 64 years and elderly persons greater than o
r equal to 65 years of age with the 23-valent pneumococcal polysaccharide v
accine. Design and setting: This was a decision-analytic modelling study fr
om the societal perspective in Belgium. The analysis compared 'vaccination'
with 'no vaccination and treatment'.
Methods: Calculations were based on the assumption that vaccination is as e
ffective against all pneumococcal infections as it is against invasive pneu
mococcal disease. Data on the incidence of pneumococcal pneumonia and menin
gitis, frequency of hospitalisation, mortality rates and vaccine effectiven
ess were derived from the international literature. Costs were derived from
analysis of historical data for cases of pneumococcal infection in Belgium
.
Results: Vaccinating 1000 adults between the ages of 18 and 64 years gains
approximately 2 life-years in comparison with the no vaccination option. Ho
w ever, to realise these additional health benefits requires additional cos
ts of 11 800 European Currency Units (ECU; 1995 values) per life-year saved
. Vaccinating 1000 elderly people (greater than or equal to 65 years) leads
to >9 life-years gained as well as a small monetary benefit of ECU1250. An
extensive sensitivity analysis did not greatly affect the results for the
elderly population: vaccination in this age group always remained favourabl
e, and thus it is clearly indicated from an economic point of view. A cruci
al assumption for both age groups is that the effectiveness of the vaccine
holds for all pneumococcal pneumonia. It is clear that the results will bec
ome less favourable if this assumption is dropped.
Conclusions: Preventing pneumococcal infections by vaccination clearly bene
fits people's health. Reimbursement can be recommended for the elderly grou
p; however more accurate epidemiological data are still needed to make deci
sions concerning routine pneumococcal vaccination in adults <65 years of ag
e. Unfortunately, the issue of whether the effectiveness of the vaccine hol
ds for all pneumococcal pneumonia is as yet unresolved in the medical liter
ature.